Navigation Links
ViroPharma to Present at Three November Healthcare Conferences
Date:11/6/2008

EXTON, Pa., Nov. 6 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the Rodman & Renshaw Annual Global Investment Conference at 12:25 P.M. ET on Wednesday, November 12, 2008. The conference is being held at the New York Palace Hotel.

ViroPharma also announced that Colin Broom, vice president, chief scientific officer of ViroPharma will present at the Lazard Capital Markets 5th Annual Healthcare Conference at 9:30 A.M. ET on Wednesday, November 19, 2008. The conference is being held at the St. Regis Hotel in New York.

William Roberts, vice president, corporate communications of ViroPharma will present at the Needham & Company Focus on Infectious Disease Conference at 9:30 A.M. ET on Thursday, November 20, 2008. The conference is being held at Needham & Company's corporate headquarters in New York.

ViroPharma's presentations will be webcast live for investors through http://www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) (vancomycin hydrochloride capsules, USP), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains, and Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, http://www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
2. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
3. ViroPharma to Present at Three October Healthcare Conferences
4. ViroPharma to Present at Three September Healthcare Conferences
5. ViroPharma To Acquire Lev Pharmaceuticals
6. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
7. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
8. ViroPharma to Present at Two Upcoming Healthcare Conferences
9. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
10. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
11. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... 21, 2017 , ... Lajollacooks4u welcomed the San Diego chapter of Les Dames ... of professional women with high achievement in the fields of food, fine beverage and ... Twelve members began with an olive oil tasting to whet their palettes and then ...
(Date:9/20/2017)... ... September 20, 2017 , ... The award-winning ... Services (Koch) to feature new innovations aimed at helping farmers solve the problem ... American Farmer airs Tuesdays at 8:30aET on RFD-TV. Check your local listings for ...
(Date:9/20/2017)... ... 20, 2017 , ... Diversity focused business accelerator, The Refinery , announced ... to uncover the top technology-driven, women-led startups in Boston, MA, New Haven/Hamden, CT, and ... entrepreneurial events going on that week – in Boston, it will be part of ...
(Date:9/20/2017)... ... September 20, 2017 , ... Proscia ... Pathology , a provider of whole slide imaging solutions, are hosting a pre-conference ... workshop, entitled “Successfully Deploying a Best-in-Class Strategy for Digital Pathology,” will feature Proscia ...
Breaking Biology Technology:
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/28/2017)... , March 28, 2017 ... Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video ... and Region - Global Forecast to 2022", published by ... in 2016 and is projected to reach USD 75.64 ... 2017 and 2022. The base year considered for the ...
(Date:3/23/2017)... Research and Markets has announced the addition of the "Global ... 2025" report to their offering. ... The Global Vehicle Anti-Theft System Market is ... next decade to reach approximately $14.21 billion by 2025. ... all the given segments on global as well as regional levels ...
Breaking Biology News(10 mins):